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There is good epidemiological evidence that patients with autoimmune rheumatic disease states, particularly rheumatoid
arthritis, have an increased risk of cardiovascular morbidity and mortality when compared to the general population. The
presence of a chronic systemic proinflammatory state in this patient group disrupts the structural and functional integrity
of the endothelium and the arterial wall, favouring the onset and progression of atherosclerosis. A significant role in the
detrimental effects of inflammation on endothelial function and vascular homeostasis is played by specific proatherosclerotic
cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). Recent systematic
reviews and meta-analyses have shown that treatment with methotrexate, a first-line disease-modifying antirheumatic drug
(DMARD), is associated with a significant reduction in atherosclerosis-mediated cardiovascular events, such as myocardial
infarction and stroke, and mortality, when compared to other DMARDs. This suggests that methotrexate might exert
specific protective effects against vascular inflammation and atherosclerosis in the context of autoimmune rheumatic
disease. This review discusses the available evidence regarding the potential antiatherosclerotic effects of methotrexate
through the inhibition of TNF-α, IL-1, and IL-6 and provides suggestions for future experimental and human studies
addressing this issue.
1. Introduction
Autoimmune rheumatic diseases such as rheumatoid arthri-
tis (RA) are characterized by the presence of a chronic
inflammatory state affecting the joints as well as a number
of other organs and tissues [1]. The prevalence of RA ranges
between 0.1 and 5%, depending on specific ethnic groups and
geographic locations, and is higher in females than in males
[1]. Patients with RA have an increased risk of death [2].
The increased mortality in this patient group, as well as
in other autoimmune rheumatic conditions, is primarily
due to a relatively high prevalence of cardiovascular
disease and its clinical consequences, mainly acute
atherosclerosis-related events such as myocardial infarction
and stroke [3–5]. The risks of myocardial infarction and
stroke are, respectively, 38% and 24% higher in RA patients
when compared to the general population [4, 5]. This
suggests that RA favours the onset of vascular damage and
atherosclerosis either through conventional cardiovascular
risk factors, such as diabetes, hypercholesterolaemia, or ciga-
rette smoking, or through alternative mechanisms [6, 7]. One
possible alternative mechanism is represented by the autoim-
mune- and inflammation-mediated disruption of the struc-
tural and/or functional integrity of the endothelium. This
leads to significant alterations in vascular homeostasis,
driven by an impairment of nitric oxide (NO) synthesis by
endothelial NO synthase (eNOS), that include a reduced
endothelium-dependent vasodilatation, an increased leuko-
cyte and monocyte adhesion to, and deposition in, the
arterial wall, an increased intima-media thickness and arte-
rial stiffness, and a prothrombotic tendency [8–13]. Notably,
these abnormalities have been reported both in animal
models of autoimmune rheumatic disease and in patients
with RA [8, 14–18]. The “inflammatory theory” of athero-
sclerosis highlights the key role of specific cytokines, particu-
larly tumour necrosis factor-alpha (TNF-α), interleukin-1
(IL-1), and interleukin-6 (IL-6), in disrupting endothelial
integrity and vascular homeostasis [19, 20]. Given the
presence of a chronic inflammatory state, and therefore a
sustained vascular insult, it is likely that the pathophysiolog-
ical role of proatherosclerotic cytokines is further augmented
in RA. This might explain the increased cardiovascular risk
reported in this patient group [7].
Over the last few years, an increasing number of in vitro
and in vivo studies have sought to identify pharmacological
strategies targeting inflammatory pathways for cardiovascu-
lar disease prevention and management [20–22]. A number
of therapeutic agents commonly prescribed to combat
immune activation and inflammation in RA might also exert
salutary effects on endothelial function and vascular homeo-
stasis. Recent epidemiological evidence suggests that
methotrexate, an established first-line disease-modifying
antirheumatic drug (DMARD), might exert protective effects
against cardiovascular disease. This review discusses the role
of cytokines and inflammation in the pathophysiology of
endothelial dysfunction and atherosclerosis, the pharmacol-
ogy of methotrexate, the reduced cardiovascular risk associ-
ated with its use, and the available evidence regarding the
effects of this DMARD on proatherosclerotic cytokines and
endothelial function.
2. Cytokines, Endothelial Dysfunction,
and Atherosclerosis
The endothelium plays a key role in maintaining vascular
homeostasis and protecting the vascular wall from a number
of endogenous and exogenous proatherosclerotic insults
[23]. A key role, in this context, is played by nitric oxide
(NO), an endogenous messenger synthesised by the enzyme
endothelial NO synthase (eNOS) [10]. NO regulates several
important physiological processes, including vasodilation of
arteries and arterioles, vascular tone, arterial stiffness, wave
reflection, peripheral vascular resistance, blood pressure,
and platelet function (Figure 1) [10]. A reduced NO synthesis
by eNOS has been shown to be associated with virtually all
cardiovascular risk factors [24]. Furthermore, clinical
measures of endothelial dysfunction independently predict
cardiovascular morbidity and mortality in several patient
groups [25–27]. Therefore, the available evidence suggests
that endothelial dysfunction is a key pathophysiological step
in the sequence of events linking the presence of one or more
cardiovascular risk factors with the development of athero-
sclerosis. Furthermore, endothelial dysfunction is useful in
stratifying the risk of cardiovascular events at the population
level and might represent an important target of therapies
designed to mitigate such risk [28].
A significant number of cytokines, a group of low-
molecular weight proteins, are produced in several cell types,
such as endothelial cells, monocytes, and vascular smooth
muscle cells, that play a key role in maintaining vascular
homeostasis. Amongst them, the cytokines TNF-α, IL-1,
and IL-6 have been extensively investigated not only from a
pathophysiological point of view but also as therapeutic
targets for novel cardioprotective therapies [21, 22, 29]. Both
TNF-α and IL-1 are known to stimulate the synthesis of IL-6
during the process of immune activation and inflammation
[30]. This, in turn, triggers several pathways that result in
endothelial dysfunction, vascular inflammation and damage,
and atherosclerosis [31]. The cellular effects of TNF-α and
IL-1 are primarily mediated by the p38 mitogen-activated
protein kinase (p38MAPK)/nuclear factor kappa-light-
chain-enhancer of the activated B-cell (NF-κB) pathways
[32]. By contrast, the effects of IL-6 are mediated by the IL-
6 receptor and the signal transducer protein gp130 [33].
Experimental studies have demonstrated the deleterious
effects of TNF-α, IL-1, and IL-6 on endothelial function,
vascular homeostasis, and cardiovascular risk and the protec-
tive effects of pharmacological agents targeting these
cytokines on surrogate vascular markers (Table 1).
2.1. TNF-α. Treatment of endothelial cells with TNF-α has
been shown to increase the expression of the inducible form
of NO synthase (iNOS), decreasing at the same time the
expression of the endothelial constitutive isoform eNOS
[34]. While the maintenance of eNOS activity provides ade-
quate NO synthesis for the regulation of several physiological
and antatherosclerotic effects, an excessive NO synthesis by
iNOS leads to the intracellular formation of reactive oxygen
species with consequent development of endothelial dysfunc-
tion, apoptosis, and vascular damage [35]. Not surprisingly,
several studies have also reported that TNF-α significantly
impairs endothelium-dependent vasodilation, through an
increase in reactive oxygen species, promotes the adhesion
of leukocytes to the endothelium, and favours endothelial cell
apoptosis [36–38]. Furthermore, TNF-α inhibits the activity
of the enzyme dimethylarginine dimethylaminohydrolase,
with consequent accumulation of the endogenous eNOS
inhibitor asymmetric dimethylarginine (ADMA) [39, 40].
This effect is clinically relevant as higher plasma concentra-
tions of ADMA have been shown to independently predict
cardiovascular events in patients with a wide range of cardio-
vascular risk at baseline (Table 1) [41, 42].
Higher serum TNF-α concentrations have been associ-
ated with an increased risk of ischaemic stroke and recurrent
coronary events in epidemiological studies [43, 44]. The key
role of TNF-α in mediating the detrimental effects of inflam-
mation on endothelial dysfunction and vascular homeostasis
is also supported by the results of animal and human studies
investigating the effects of specific TNF-α inhibitors. For
example, treatment with adalimumab significantly reduced
the adhesion of human leukocytes to endothelial cells and
the expression of vascular cell adhesion molecule-1
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(VCAM-1), intracellular adhesion molecule-1 (ICAM-1),
and E-selectin [45]. Other studies have shown that treatment
with adalimumab or etanercept improved clinical measures
of endothelium-dependent vasodilation in patients with pso-
riasis, reduced the plasma concentrations of ADMA, and
increased circulating endothelial progenitor cells in patients
with RA (Table 1) [46–48].
2.2. IL-1. Increased production of IL-1 has been shown to
induce leukocyte adhesion to the endothelium, exert procoa-
gulant activity, and stimulate the growth and chemotaxis of
vascular smooth muscle cells, key steps in the pathogenesis
of atherosclerosis [49–52]. In animal studies, exposure to
exogenous IL-6 causes an increase in coronary vasospastic
responses to pharmacological challenge and intima thicken-
ing (Table 1) [53]. Moreover, multiple factors known to asso-
ciate with atherosclerosis, such as cholesterol crystals,
atheroprone oscillatory flow, hypoxia, and neutrophil extra-
cellular traps, have recently been found to activate the critical
IL-1beta producing NLRP3 inflammasome [22].
Polymorphisms in the IL-1 receptor antagonist (IL-1Ra)
gene have been shown to have significant associations with
the presence of single-vessel coronary artery disease, assessed
by coronary angiography, in patients with ischaemic heart
disease [54]. Conversely, pharmacological inhibition of IL-1
with anakinra reduces the concentrations of the potent
endogenous vasoconstrictor endothelin-1 and arterial stiff-
ness and improves clinical measures of endothelial function
in patients with RA [55]. Similar effects of anakinra on
endothelium-dependent vasodilation have been reported in
animal models of diabetes (Table 1) [56]. In a recently com-
pleted randomized placebo-controlled trial in 10,061 partici-
pants with a previous myocardial infarction and C-reactive
protein concentrations ≥2mg/L, canakinumab, a monoclo-
nal antibody targeting IL-1beta, significantly reduced the
primary end-point of nonfatal myocardial infarction, nonfa-
tal stroke, or cardiovascular death after a median follow-up of
3.7 years. Of the three subcutaneous doses of canakinumab
studied (50mg, 150mg, and 300mg every three months),
only the 150mg dose met the prespecified multiplicity
adjusted threshold for statistical significance. Furthermore,
there were no significant differences in all-cause mortality
between treatment with canakinumab and placebo [57].
2.3. IL-6. IL-6 has been shown to upregulate the expres-
sion of the angiotensin II type-1 receptor in vascular smooth
muscle cells, responsible for vasoconstriction, cell apoptosis,
and proinflammatory effects, and to impair endothelium-
dependent vasodilation in animal models [58]. Increased
plasma IL-6 concentrations are significantly associated with
a reduced endothelium-dependent vasodilation both in
healthy subjects [59] and in patients with hypertension [60]
or hypercholesterolaemia [61]. A significant association
between plasma IL-6 concentrations and clinical markers of
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Figure 1: Endothelium, nitric oxide, and vascular homeostasis. NO: nitric oxide; VSMC: vascular smooth muscle cell.
Table 1: Effects of the cytokines TNF-α, IL-1, and IL-6 on




Endothelial nitric oxide synthase activity ↓
Inducible nitric oxide synthase activity ↑
Reactive oxygen species ↑
Endothelium-dependent vasodilation ↓
Leukocyte adhesion ↑



















↑: Increase; ↓: decrease.
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hypertension (Table 1) [62]. A meta-analysis performed by
the Emerging Risk Factors Collaboration has also shown that
higher plasma IL-6 concentrations predict the risk of nonfa-
tal myocardial infarction and coronary artery disease-related
death, with a 25% increase in the risk of future vascular
events for each increase in log IL-6 concentrations (RR
1.25, 95% CI 1.19 to 1.32) [63].
Furthermore, treatment with the IL-6 receptor inhibitor
tocilizumab caused an increase in endothelium-dependent
vasodilatation, and a concomitant reduction in arterial stiff-
ness, in patients with RA [64, 65]. In another study, toci-
lizumab improved endothelial function and reduced
markers of oxidative stress, inflammation, and thrombosis
in patients with RA (Table 1) [66].
3. Methotrexate Pharmacology
Methotrexate, an analogue of the B vitamin folic acid, is a
first-line synthetic DMARD for the management of RA and
other autoimmune diseases that is normally administered
once a week, either orally, subcutaneously, or intramuscu-
larly, with doses ranging between 5 and 25mg [67, 68]. Nota-
bly, methotrexate is the only DMARD that has demonstrated
significant survival benefits in patients with RA [69–71].
After being transported into the cytoplasm, through the
reduced folate carrier, methotrexate is converted into intra-
cellular polyglutamates. The polyglutamate forms ensure
the intracellular retention of methotrexate, allowing weekly
administration despite the relatively short plasma elimina-
tion half-life (5–8 hours) [72]. The polyglutamates also
mediate the immunomodulating and anti-inflammatory
effects of methotrexate, by reducing the synthesis of purines,
pyrimidines, and DNA through the inhibition of dihydrofo-
late reductase, thymidylate synthase, and aminoimidazole
carboxamide ribonucleotide (AICAR) transformylase
(ATIC, Figure 2) [73–75]. Furthermore, the inhibition of
ATIC causes the accumulation of the substrate AICAR
which, in turn, inhibits the enzymes adenosine deaminase
and adenosine monophosphate (AMP) deaminase, involved
in the catabolism of adenosine (Figure 2) [75]. Adenosine
per se exerts significant anti-inflammatory effects, primarily
through the A2A and A3 receptors [76], and mediates the
anti-inflammatory effects of methotrexate. In animal models
of inflammation, methotrexate has been shown to increase
AICAR and adenosine concentrations and to inhibit the
accumulation of leukocytes, in exudates from carrageenan-
inflamed air pouches. The administration of AMP deaminase
partly reversed the methotrexate-mediated reduction in leu-
kocyte accumulation. Additionally, the administration of
3,7-dimethyl-1-propargylxanthine, an A2A receptor antago-
nist, but not 8-cyclopentyl-dipropylxanthine, an A1 receptor
antagonist, suppressed the methotrexate-mediated reduction
in leukocyte accumulation [77]. Furthermore, both AICAR
and AMP activate the 5′ adenosine monophosphate-
activated protein kinase (AMPK) [78]. AMPK activation is
protective towards endothelial cell function and vascular
homeostasis, by ensuring physiological NO synthesis, main-
taining mitochondrial structure and function, and prevent-
ing oxidative stress and apoptosis [79]. Moreover, a role for
AMPK in inhibiting vascular smooth muscle cell prolifera-
tion, a key proatherosclerotic event both in autoimmune
rheumatic diseases and in the general population, has been
proposed [80, 81]. There is experimental evidence that
AMPK is a key mediator of the effects of methotrexate on
inflammation and endothelial function. In vitro studies have
shown that methotrexate, at concentrations between 0.1 and
0.5μM, increased AMPK phosphorylation and AMPK activ-
ity in perivascular adipose tissue cells. In these cells, the
administration of palmitic acid, a proinflammatory agent,
decreased AMPK phosphorylation; however, these effects
were significantly reduced by pretreatment with either meth-
otrexate or AICAR. Furthermore, methotrexate significantly
reduced the phosphorylation of NF-κB p65 and prevented
the palmitic acid-mediated increase in the expression of
TNF-α and IL-6, indicating anti-inflammatory effects. Silenc-
ing AMPK with AMPKa1/2-specific siRNA significantly
decreased the inhibitory effects of methotrexate on palmitic
acid-mediated NF-κB p65 phosphorylation and on the
expression of TNF-α and IL-6. Pretreatment with methotrex-
ate prevented the impairment of acetylcholine-induced,
endothelium-dependent vasodilation in rat aorta following
palmitic acid administration. Notably, the protective effects
of methotrexate on endothelial function were attenuated by
cotreatment with compound C, an AMPK inhibitor [82].
4. Methotrexate and Cardiovascular Risk
Recent systematic reviews and meta-analyses have investi-
gated the associations between methotrexate treatment and
cardiovascular risk. Micha et al. identified observational
studies in 66,334 patients with either RA (9 studies), psoriasis
(1 study), or polyarthritis (1 study), that reported 6235



















Figure 2: Intracellular effects of methotrexate. DHFR: dihydrofolate
reductase; TYMS: thymidylate synthase; ATIC: aminoimidazole
carboxamide ribonucleotide (AICAR) transformylase; FAICAR:
5-formamidoimidazole-4-carboxamide ribotide; IMP: inosine
monophosphate; AMP: adenosine monophosphate; AMPK:
5′ adenosine monophosphate-activated protein kinase; ADA:
adenosine deaminase; 5′-NT: 5′-nucleotidase; −: inhibition; +:
activation.
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these studies was 5.8 years. Six studies compared methotrex-
ate users versus never users, three compared current versus
noncurrent users, and two compared initiators versus
noninitiators. Cardiovascular endpoints included total or
fatal cardiovascular disease (7 studies; two studies also
provided separate estimates for myocardial infarction
and ischaemic/haemorrhagic stroke), myocardial infarc-
tion (3 studies), and ischaemic stroke (1 study). Combined
assessment of the included studies showed that methotrexate
treatment was associated with a significant reduction in
cardiovascular events (RR 0.79, 95% CI 0.73 to 0.87). Assess-
ment of specific cardiovascular endpoints showed a similar
effect size (overall cardiovascular disease events: RR 0.76,
95% CI 0.69 to 0.84; myocardial infarction: RR 0.82, 95%
CI 0.71 to 0.96; stroke: RR 0.70, 95% CI 0.56 to 0.87) [83].
In a subsequent systematic review and meta-analysis, Rou-
bille et al. identified 34 studies (28 studies in 236,525 RA
patients, reporting 5410 cardiovascular events, and 6 studies
in 220,209 patients with either psoriasis or psoriatic arthritis,
reporting 2701 cardiovascular events). In studies conducted
in RA patients, methotrexate use was associated with a
reduced risk of all cardiovascular events (RR 0.72, 95% CI
0.57 to 0.91, P = 0 007) and myocardial infarction (RR 0.81,
95% CI 0.68 to 0.86, P = 0 01) when compared to other syn-
thetic DMARDs. Although there was no significant effect of
methotrexate on the risk of either stroke (RR 0.78, 95% CI
0.40 to 1.50) or major adverse cardiovascular events (RR
0.38, 95% CI 0.05 to 2.84), the number of studies assessing
these endpoints was relatively low (one study for stroke and
two studies for major adverse cardiovascular events, resp.)
[84]. Therefore, the results of observational studies support
the hypothesis that methotrexate exhibits specific protective
cardiovascular effects when compared to other DMARDs.
5. Methotrexate and
Proatherosclerotic Cytokines
In order to review the available evidence on the direct or indi-
rect, mediated by adenosine, AICAR or AMPK activation,
effects of methotrexate on proatherosclerotic cytokines, a
PubMed literature search was conducted from inception to
June 2017, using the following terms: methotrexate, adeno-
sine, AICAR, AMPK, endothelium, inflammation, athero-
sclerosis, TNF-α, IL-1, and IL-6.
5.1. TNF-α. In in vitro studies, clinical concentrations of
methotrexate (2× 10−8M and 2× 10−7M) have been shown
to increase the release of soluble TNF receptor p75 from
the cell surface [85]. This phenomenon is able to significantly
inhibit the proinflammatory effects of TNF-α [86]. Adeno-
sine is a known inhibitor of TNF-α expression through
stimulation of the A3 receptor (Table 2) [87, 88]. There is
recent evidence that methotrexate stimulates AMPK phos-
phorylation and activity, induces manganese superoxide dis-
mutase mRNA and protein, and increases the expression
of the cytoprotective genes haem oxygenase-1 and Bcl-2-
related protein in human umbilical vein endothelial cells
(HUVECs) and arterial endothelial cells (HAECs). The
pretreatment of endothelial cells with TNF-α did not affect
the methotrexate-mediated upregulation of manganese
superoxide dismutase and haem oxygenase-1 mRNA [89].
Methotrexate (10−8M to 10−6M) and/or adenosine treat-
ment has also been shown to prevent the TNF-α-induced
(a) expression of ICAM-1 and VCAM-1 in human
Table 2: Effects of methotrexate, adenosine, AICAR, and AMPK
activation on endothelial function and vascular homeostasis.
Mediator Reported effects
Methotrexate







Mitochondrial mass, membrane potential, and









Mitochondrial mass, membrane potential, and
intracellular ATP concentrations ↑













Endoplasmic reticulum stress ↓
Manganese superoxide dismutase induction ↑
NF-κB ↓
Monocyte adhesion to endothelial cells ↓
Restenosis ↓
Cholesterol efflux capacity ↑
Cellular glucose uptake ↑
Glycolysis ↑
AICAR: aminoimidazole carboxamide ribonucleotide; AMPK: 5′ adenosine
monophosphate-activated protein kinase; TNF-α: tumour necrosis factor-
alpha; IL-1: interleukin-1; IL-6: interleukin-6; ICAM-1: intercellular
adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1; ATP:
adenosine triphosphate; eNOS: endothelial nitric oxide synthase; NF-κB:
nuclear factor kappa-light-chain-enhancer of the activated B-cell; NO:
nitric oxide; ↑: increase; ↓: decrease.
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umbilical vein endothelial cells (HUVEC) [90] and (b)
reduction of mitochondrial mass, membrane potential,
and intracellular ATP concentrations, in endothelial cells
through increased activity of eNOS [91]. Furthermore,
adenosine has been shown to reduce the circulating con-
centrations of TNF-α and IL-6 in a mice model of sepsis
(Table 2) [92]. By contrast, therapeutic concentrations of
methotrexate, 0.1, 0.25, and 0.5μM, significantly increased
the expression of the TNF-α receptor-associated factor 1
gene (~threefold change) and of the TNF-α receptor
superfamily member 9 gene (~threefold change) in EA.hy
926 cells, derived from the fusion of primary endothelial
cells with an epithelial tumour cell line [93].
5.2. IL-1. In an in vitromodel of palmitate-induced endothe-
lial dysfunction, AICAR-mediated AMPK activation has
been shown to significantly reduce IL-1, IL-6, and VCAM-1
synthesis, by preventing the activation of the NLRP3 inflam-
masome [94]. Similarly, pharmacological activation of
AMPK with oestradiol prevented the IL-1-induced expres-
sion of VCAM-1 and ICAM-1 in cultured human endothelial
cells (Table 2) [95]. By contrast, therapeutic concentrations
of methotrexate, 0.1, 0.25, and 0.5μM, significantly increased
the expression of the IL-1 alpha gene (~threefold change)
and of the IL-1 receptor-like 1 gene (~fourfold change) in
EA.hy 926 cells [93].
5.3. IL-6. In db/db mice fed with Western diet, methotrexate
treatment (4mg/kg) caused a significant reduction in the
circulating concentrations of IL-6 and TNF-α. These effects
were associated with a significant increase in endothelium-
dependent vasodilatation and a reduction in VCAM-1 [96].
In another study, methotrexate treatment (0.1–0.5μM) sig-
nificantly reduced the expression of IL-6 and TNF-α. These
effects were mediated by the activation of AMPK and were
associated with an improvement in eNOS activity and
endothelium-dependent vasodilation in rat aorta (Table 2)
[82]. Adenosine has been shown to prevent the thrombin-
mediated increased expression of IL-6, VCAM-1, ICAM-1,
and E-selectin in HUVECs. These effects are mediated by
the activation of the adenosine receptor A2A [97]. Similarly,
adenosine inhibited, in a dose-dependent fashion, the release
of IL-6, VCAM-1, and ICAM-1 in HUVECs pretreated with
either IL-1, TNF-α, or lipopolysaccharide (Table 2) [98].
6. Additional Vascular Effects of Adenosine,
AICAR, and AMPK Activation
A number of studies have shown that adenosine, AICAR, and
AMPK activation provide beneficial effects on endothelial
function and vascular homeostasis that are independent of
those on TNF-α, IL-1, or IL-6.
6.1. Adenosine Accumulation. There is good evidence that
adenosine, through the activation of the A2A and A2B recep-
tors, lowers blood pressure as a result of increased NO syn-
thesis in the endothelium and direct vasodilation [99, 100].
Studies have also demonstrated the presence of central
nervous system-mediated hypotensive effects through the
activation of the A3 receptor [101]. Furthermore, the phar-
macological activation of the A2B receptor prevents the for-
mation of atherosclerotic lesions and reduces the plasma
concentrations of cholesterol and triglycerides, possibly
through the reduced activation of the transcription factor
sterol regulatory element-binding protein 1 in the liver
[102, 103]. Activation of adenosine receptors seems also to
modulate glucose homeostasis. However, the pathophysio-
logical and clinical relevance of this finding is yet to be
determined (Table 2) [104].
6.2. AICAR and Activation of 5′ Adenosine Monophosphate-
Activated Protein Kinase (AMPK). There is increasing
evidence that AICAR and or/AMPK activation stimulates
NO synthesis in the endothelium, enhances endothelium-
dependent and endothelium-independent vasodilation,
reduces blood pressure, prevents vessel restenosis, and
increases cholesterol efflux capacity [105–110]. Furthermore,
AMPK stimulates cellular glucose uptake, through GLUT-1
and GLUT-4 transporters, and glycolysis, through phosphor-
ylation of two isoforms of the enzyme 6-phoshofructo-2-
kinase: fructose-2,6-biphosphatase, with beneficial effects
on glucose homeostasis [111–114]. There is also evidence
that AMPK activation protects endothelial cells from the del-
eterious effects of chronic exposure to high concentrations of
glucose and fatty acids and consequently reduces oxidative
stress, inflammation, and endoplasmic reticulum stress
(Table 2) [115, 116].
7. Discussion
The available evidence from systematic reviews and meta-
analyses of observational studies in patients with either RA
or other autoimmune rheumatic disease states suggests that
the use of methotrexate is associated with a significant reduc-
tion in cardiovascular morbidity and mortality when com-
pared to other DMARDs. Furthermore, a relatively small
number of experimental studies have shown that methotrex-
ate can exert beneficial effects on endothelial function and
vascular homeostasis by preventing or blocking the effects
of key proatherosclerotic cytokines such as TNF-α, IL-1,
and IL-6. The reported effects are mediated either by metho-
trexate directly or through the activation of adenosine
receptors, AICAR, or AMPK (Table 2). Pending further
in vitro and in vivo studies investigating the exact mecha-
nisms involved in such effects, a number of limitations
need to be considered when interpreting the available data:
(1) The dose of methotrexate used in some studies [96]
and its consequent local concentrations in target cells
and tissues are quite different from those normally
observed in patients with autoimmune disorders.
(2) No study has assessed the intracellular concentrations
of methotrexate polyglutamates, as a factor mediating
the effects of the drug on the study end-points.
(3) The effects of methotrexate, adenosine, AICAR, or
AMPK activation on proatherosclerotic cytokines
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were not compared to those of other synthetic or
biologic DMARDs.
(4) Other studies, not specifically investigating TNF-α,
IL-1, and IL-6, have shown that methotrexate can also
exert antiproliferative effects in human umbilical vein
endothelial cells and EA.hy 926 cells [93, 117, 118]
and reduce NO synthesis, possibly as a result of
reduced availability of tetrahydrobiopterin, an essen-
tial cofactor for endothelial nitric oxide synthase, sec-
ondary to dihydrofolate reductase inhibition [119].
(5) There is no direct evidence that the methotrexate-
induced inhibition of TNF-α, IL-1, or IL-6 leads to
sustained beneficial effects on endothelial function,
atherosclerosis, arterial structure and function, and
cardiovascular risk in human studies.
These issues should be accounted for in future studies
investigating the effects of methotrexate on proathero-
sclerotic cytokines. In particular, the use of other DMARDs
as comparator should help to determine whether methotrex-
ate treatment exerts specific antiatherosclerotic effects that
might help to explain its superiority, in terms of cardiovascu-
lar risk reduction, reported in observational studies. Further-
more, a comprehensive assessment of proatherosclerotic and
antiatherosclerotic cytokines, such as transforming growth
factor-β, IL-10, and IL-35 [120], as well as measures of
endothelial cell proliferation, apoptosis, and nitric oxide
synthesis, might provide additional mechanistic insights
regarding the possible vasculoprotective effects of metho-
trexate and the potential rationale for combining metho-
trexate treatment with other interventional strategies
targeting specific cytokines. In this context, the results
of the Cardiovascular Inflammation Reduction Trial
(CIRT, clinicaltrials.gov identifier NCT01594333), investi-
gating the effects of methotrexate on myocardial infarc-
tion, stroke, and cardiovascular death in patients with
type 2 diabetes or metabolic syndrome and stable coronary
artery disease, will provide additional knowledge regarding
the potential repurposing of methotrexate for cardiovascu-
lar risk management and prevention in different patient
populations [121].
8. Conclusions
The evidence recently generated from experimental studies
suggests that methotrexate, an anchor drug in the treat-
ment of RA and other autoimmune disorders, might exert
significant beneficial effects on endothelial function and
vascular homeostasis by targeting key cytokines regulating
the immune responses and inflammation pathways responsi-
ble for the development of atherosclerosis and thrombosis.
However, further studies are required to fully establish
the role of this DMARD as an antiatherosclerotic and car-
dioprotective agent.
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